Physician profile
Albert Khaski
NPI 1396747622
$2,284.04
in general payments reported to CMS, 2019-2025
19 companies · $16.66 in 2025
The $16.66 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $162 · 2021: $703 · 2022: $457 · 2023: $281 · 2024: $16.82 · 2025: $16.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.63 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $603.98 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $432.97 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.35 | 2019 | |
| Novo Nordisk INC | $275.51 | 2019-2025 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $121.10 | 2020-2021 | |
| Amgen INC. | $98.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $63.63 | 2022 | |
| Merck Sharp & Dohme LLC | $50.51 | 2021-2023 | Verquvo |
| Nestle Healthcare Nutrition INC. | $36.11 | 2023 | |
| Boston Scientific Corporation | $30.46 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $29.75 | 2022 | |
| Pfizer INC. | $29.67 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.42 | 2021 | |
| Alfasigma USA, INC. | $20.14 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.88 | 2019 | |
| Lilly USA, LLC | $13.26 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Khaski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.